Literature DB >> 26692386

High risk HPV testing following treatment for cervical intraepithelial neoplasia.

M Molloy1, R Comer2, P Rogers2, M Dowling3, P Meskell3, K Asbury2, M O'Leary2.   

Abstract

AIM: To determine the results of combined cytology and high-risk human papilloma virus (HR HPV) tests at 6 and 18 months postcolposcopy treatment at one Irish colposcopy centre.
METHODS: All women who attended the centre's colposcopy smear clinic for a co-test 6 months (initial test) posttreatment were included in the audit (n = 251).
RESULTS: The results revealed negative HR HPV for 79 % (n = 198) of women tested 6 months after treatment and positive results for 21 % (n = 53). HR HPV testing was more sensitive than cytology and led to early detection of residual disease. No women with negative HR HPV had high-grade cytology.
CONCLUSION: HR HPV is more sensitive than cytology for detection of persistent CIN. However, 19 women with positive HR HPV had normal colposcopy with no persistent CIN detected. A national cost-benefit analysis is recommended to determine the value of the second co-test.

Entities:  

Keywords:  Audit; Cervical intraepithelial neoplasia; Colposcopy; HPV DNA tests; Papanicolaou test

Mesh:

Year:  2015        PMID: 26692386     DOI: 10.1007/s11845-015-1392-4

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  10 in total

1.  Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.

Authors:  J Verguts; B Bronselaer; G Donders; M Arbyn; J Van Eldere; M Drijkoningen; W Poppe
Journal:  BJOG       Date:  2006-09-15       Impact factor: 6.531

Review 2.  Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis.

Authors:  M Kyrgiou; G Koliopoulos; P Martin-Hirsch; M Arbyn; W Prendiville; E Paraskevaidis
Journal:  Lancet       Date:  2006-02-11       Impact factor: 79.321

Review 3.  EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.

Authors:  Marc Arbyn; Silvia de Sanjosé; Mona Saraiya; Mario Sideri; Joel Palefsky; Charles Lacey; Maura Gillison; Laia Bruni; Guglielmo Ronco; Nicolas Wentzensen; Julia Brotherton; You-Lin Qiao; Lynnette Denny; Jacob Bornstein; Laurent Abramowitz; Anna Giuliano; Massimo Tommasino; Joseph Monsonego
Journal:  Int J Cancer       Date:  2012-07-02       Impact factor: 7.396

4.  Prediction of residual/recurrent disease by HPV genotype after loop excision procedure for high-grade cervical intraepithelial neoplasia with negative margins.

Authors:  Dongmei Wu; Yizhen Zheng; Wei Chen; Ciren Guo; Jiang Yu; Guilin Chen; Yanling Huang
Journal:  Aust N Z J Obstet Gynaecol       Date:  2011-01-31       Impact factor: 2.100

5.  Is colposcopy necessary at twelve months after large loop excision of the transformation zone? A clinical audit.

Authors:  Valerie Thompson; Raymond Marin
Journal:  Aust N Z J Obstet Gynaecol       Date:  2013-12       Impact factor: 2.100

6.  HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia.

Authors:  H C Kitchener; P G Walker; L Nelson; R Hadwin; J Patnick; G B Anthony; A Sargent; J Wood; C Moore; M E Cruickshank
Journal:  BJOG       Date:  2008-05-22       Impact factor: 6.531

Review 7.  Understanding HPV tests and their appropriate applications.

Authors:  H A Cubie; K Cuschieri
Journal:  Cytopathology       Date:  2013-09-02       Impact factor: 2.073

Review 8.  A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions.

Authors:  J Cuzick; P Sasieni; P Davies; J Adams; C Normand; A Frater; M van Ballegooijen; E van den Akker-van Marle
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

9.  Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia.

Authors:  M A Nobbenhuis; C J Meijer; A J van den Brule; L Rozendaal; F J Voorhorst; E K Risse; R H Verheijen; T J Helmerhorst
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

10.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.

Authors:  Guglielmo Ronco; Joakim Dillner; K Miriam Elfström; Sara Tunesi; Peter J F Snijders; Marc Arbyn; Henry Kitchener; Nereo Segnan; Clare Gilham; Paolo Giorgi-Rossi; Johannes Berkhof; Julian Peto; Chris J L M Meijer
Journal:  Lancet       Date:  2013-11-03       Impact factor: 79.321

  10 in total
  3 in total

1.  Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study.

Authors:  Riina Aarnio; Ellinor Östensson; Matts Olovsson; Inger Gustavsson; Ulf Gyllensten
Journal:  BMC Cancer       Date:  2020-07-13       Impact factor: 4.430

2.  A Systematic Review of Tests for Postcolposcopy and Posttreatment Surveillance.

Authors:  Megan A Clarke; Elizabeth R Unger; Rosemary Zuna; Erin Nelson; Teresa M Darragh; Miriam Cremer; Colleen K Stockdale; Mark H Einstein; Nicolas Wentzensen
Journal:  J Low Genit Tract Dis       Date:  2020-04       Impact factor: 3.842

3.  Reporting and Assessing the Quality of Diagnostic Accuracy Studies for Cervical Cancer Screening and Management.

Authors:  Megan A Clarke; Teresa M Darragh; Erin Nelson; Elizabeth R Unger; Rosemary Zuna; Miriam Cremer; Colleen K Stockdale; Mark H Einstein; Nicolas Wentzensen
Journal:  J Low Genit Tract Dis       Date:  2020-04       Impact factor: 3.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.